NOS3 and prostate carcinoma: DXT-M’s liver-protective effects may involve targets such as JUN, NOS3, and TP53, which function through relaxin, estrogen, and HIF-1 signalling pathways, and may also influence cancer-related pathways, including prostate cancer and VEGF signalling.